---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003205"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:48:57.291523+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Predictive Oncology Q1 loss $2.3M; revenue up to $110k; cash position improves to $3.1M

## Summary
- Net loss from continuing ops $2.3M ($0.32 per share) vs $0.88 loss per share YoY.
- Revenue $110,310 vs $4,858 YoY, driven by completion of tumor-specific 3D model.
- Cash and equivalents $3.1M at March 31, 2025, up from $611k at Dec 31, 2024.
- Sold Skyline Medical assets to DeRoyal; sharpens focus on AI/ML drug discovery.
- Plans European launch of ChemoFx assay for ovarian/gynecological cancers; expanded US availability.

## SEC filing metadata
- accession: 0001171843-25-003205
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184325003205/0001171843-25-003205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184325003205/f8k_051425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003205
- JSON: https://secwatch.observer/filing/0001171843-25-003205.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.